Neomycin and Polymyxin B sulfates and Hydrocortisone
- Product NDC
- 81607-014
- Requested package NDC
- 81607-014-10
- 11-digit product format
- 816070014
- Labeler code
- 81607
- Product ID
- 81607-014_d432f97b-7f75-4a04-96a7-de9c9124824c
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Neomycin and Polymyxin B sulfates and Hydrocortisone
- Dosage form
- SOLUTION/ DROPS
- Route
- AURICULAR (OTIC)
- Labeler
- Orbicular Pharmaceutical Technologies Private Limited
- Application
- ANDA220938
- Marketing category
- ANDA
- Marketing start
- 2026-10-08
- Substance
- NEOMYCIN SULFATE; POLYMYXIN B SULFATE; HYDROCORTISONE
- Active strength
- 3.5; 10000; 10 mg/mL; [iU]/mL; mg/mL
- Pharmacologic classes
- Aminoglycoside Antibacterial [EPC], Aminoglycosides [CS], Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC], Polymyxin-class Antibacterial [EPC], Polymyxins [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A220938-001 | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | SOLUTION/DROPS / OTIC | AT | 2026-08-27 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A220938-001 | AT |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A220938-001 | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | SOLUTION/DROPS / OTIC | AT | 2026-08-27 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A220938-001 | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | SOLUTION/DROPS / OTIC | AT | 2026-08-27 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A220938-001 | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | SOLUTION/DROPS / OTIC | AT | 2026-08-27 | 84e616aacf4f… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A220938-001 | AT | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A220938-001 | AT | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A220938-001 | AT | 1 | 84e616aacf4f… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Neomycin and Polymyxin B sulfates and Hydrocortisone
- Brand name suffix
- OTIC
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| NEOMYCIN SULFATE | 3.5 mg/mL |
| POLYMYXIN B SULFATE | 10000 [iU]/mL |
| HYDROCORTISONE | 10 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 057Y626693 | Internal UNII lookup |
| 19371312D4 | Internal UNII lookup |
| WI4X0X7BPJ | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 204423 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 5eae31aa-ec63-4b93-9859-8d718a8ac8ef | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Neomycin and Polymyxin B sulfates and Hydrocortisone OTIC | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | Orbicular Pharmaceutical Technologies Private Limited | 5eae31aa-ec63-4b93-9859-8d718a8ac8ef | 2026-10-14 | Warnings, Adverse reactions | 220938 ANDA220938 81607-014-10 81607-014 81607001410 |
| Neomycin and Polymyxin B sulfates and Hydrocortisone OTIC | NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | Hikma Pharmaceuticals USA Inc. | 2846b507-f92d-45e0-9807-f68bdf4de56c | 2026-09-07 | Warnings, Adverse reactions | 220938 ANDA220938 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 81607-014-10 | 81607001410 | 1 BOTTLE, DROPPER in 1 CARTON (81607-014-10) / 10 mL in 1 BOTTLE, DROPPER | 2026-10-08 | No | No | Current |